Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy

Journal of Pathology

Volumn 228, Issue 1, 2012, Pages 77-87

  Percival, Justin M ^a   Whitehead, Nicholas P ^a   Adams, Marvin E ^a   Adamo, Candace M ^b   Beavo, Joseph A ^b   Froehner, Stanley C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cGMP; diaphragm; dystrophin; fibrosis; mdx; MMP 13; nitric oxide; PDE5; sildenafil; TNF

Indexed keywords

COLLAGENASE 3; PHOSPHODIESTERASE V; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING MUSCLE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FATIGUE; LUNG FIBROSIS; MALE; MOUSE; MUSCLE CONTRACTILITY; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; CREATINE KINASE; CYCLIC GMP; DIAPHRAGM; DISEASE MODELS, ANIMAL; EVANS BLUE; FIBROSIS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY, DUCHENNE; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 84864773923     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4054     Document Type: Article

References (60)

1. Hoffman EP, Brown RH Jr, Kunkel LM,. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
2. Finsterer J, Stöllberger C,. The heart in human dystrophinopathies. Cardiology 2003; 99: 1-19.
3. Chen YW, Nagaraju K, Bakay M, et al., Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy. Neurology 2005; 65: 826-834.
4. Tidball JG, Wehling-Henricks M,. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol 2005; 17: 707-713.
5. Bernasconi P, Torchiana E, Confalonieri P, et al., Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995; 96: 1137-1144.
6. Hantaïi D, Labat-Robert J, Grimaud JA, et al., Fibronectin, laminin, type I, III and IV collagens in Duchenne's muscular dystrophy, congenital muscular dystrophies and congenital myopathies: an immunocytochemical study. Connect Tissue Res 1985; 13: 273-281.
7. Desguerre I, Mayer M, Leturcq F, et al., Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. Neuropathol Exp Neurol 2009; 68: 762-773.
8. Thomas GD, Sander M, Lau KS, et al., Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 1998; 95: 15090-15095.
9. Thomas GD, Shaul PW, Yuhanna IS, et al., Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ Res 2003; 92: 554-560.
10. Suzuki N, Motohashi N, Uezumi A, et al., NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 2007; 117: 2468-2476.
11. Percival JM, Anderson KN, Gregorevic P, et al., Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS One 2008; 3: e3387.
12. Percival JM, Anderson KN, Huang P, et al., Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle. J Clin Invest 2010; 120: 816-826.
13. Percival JM, Adamo CM, Beavo JA, et al., Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of Duchenne muscular dystrophy. Handb Exp Pharmacol 2011; 204: 323-344.
14. Percival JM,. nNOS regulation of skeletal muscle fatigue and exercise performance. Biophys Rev 2011; 3: 209-217.
15. Brenman JE, Chao DS, Xia H, et al., Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995; 82: 743-752.
16. Chang WJ, Iannaccone ST, Lau KS, et al., Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 1996; 93: 9142-9147.
17. Ito K, Kimura S, Ozasa S, et al., Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet 2006; 15: 2266-2275.
18. Sato K, Yokota T, Ichioka S, et al., Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. Acta Myol 2008; 27: 30-36.
19. Asai A, Sahani N, Kaneki M, et al., Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2007; 2: e806.
20. Kobayashi YM, Rader EP, Crawford RW, et al., Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008; 456: 511-515.
21. Wehling M, Spencer MJ, Tidball JG,. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001; 155: 123-131.
22. Wehling-Henricks M, Jordan MC, Roos KP, et al., Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005; 14: 1921-1933.
23. Lai Y, Thomas GD, Yue Y, et al., Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009; 119: 624-635.
24. Cvelich RG, Roberts SC, Brown JN,. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. Ann Pharmacother 2011; 45: 1551-1558.
25. Hofmann F, Feil R, Kleppisch T, et al., Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006; 86: 1-23.
26. Craven KB, Zagotta WN,. CNG and HCN channels: two peas, one pod. Annu Rev Physiol 2006; 68: 375-401.
27. Adamo CM, Dai DF, Percival JM, et al., Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010; 107: 19079-19083.
28. Khairallah M, Khairallah RJ, Young ME, et al., Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A 2008; 105: 7028-7033.
29. Stedman HH, Sweeney HL, Shrager JB, et al., The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991; 352: 536-539.
30. Gregorevic P, Plant DR, Leeding KS, et al., Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol 2002; 161: 2263-2272.
31. Yang L, Luo J, Petrof BJ,. Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (mdx) mouse diaphragm. Muscle Nerve 1998; 21: 394-397.
32. Hinkle RT, Lefever FR, Dolan ET, et al., Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. BMC Med 2007; 5: 18.
33. Dellorusso C, Crawford RW, Chamberlain JS, et al., Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 2001; 22: 467-475.
34. Lynch GS, Hinkle RT, Faulkner JA,. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment. Exp Physiol 2000; 85: 295-299.
35. Baltgalvis KA, Call JA, Nikas JB, et al., Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve 2009; 40: 443-454.
36. Wehling-Henricks M, Oltmann M, Rinaldi C, et al., Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. Hum Mol Genet 2009; 18: 3439-3451.
37. Zhou L, Lu H,. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol 2010; 69: 771-776.
38. Porreca E, Guglielmi MD, Uncini A, et al., Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost 1999; 81: 543-546.
39. Saito K, Kobayashi D, Komatsu M, et al., A sensitive assay of tumor necrosis factor alpha in sera from Duchenne muscular dystrophy patients. Clin Chem 2000; 46: 1703-1704.
40. Huang P, Zhao XS, Fields M, et al., Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J 2009; 23: 2539-2548.
41. Gosselin LE, Martinez DA,. Impact of TNF-alpha blockade on TGF-beta1 and type I collagen mRNA expression in dystrophic muscle. Muscle Nerve 2004; 30: 244-246.
42. Borden P, Solymar D, Sucharczuk A, et al., Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J Biol Chem 1996; 271: 23577-23581.
43. Cohn RD, van Erp C, Habashi JP, et al., Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature Med 2007; 13: 204-210.
44. Heydemann A, Ceco E, Lim JE, et al., Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest 2009; 119: 3703-3712.
45. Coirault C, Pignol B, Cooper RN, et al., Severe muscle dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. J Appl Physiol 2003; 94: 1744-1750.
46. Faulkner JA, Ng R, Davis CS, et al., Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clin Exp Pharmacol Physiol 2008; 35: 725-729.
47. Tracey KJ, Cerami A,. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9: 317-343.
48. Walley KR, Hebert PC, Wakai Y, et al., Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. J Appl Physiol 1994; 76: 1060-1067.
49. Wilcox PG, Wakai Y, Walley KR, et al., Tumor necrosis factor alpha decreases in vivo diaphragm contractility in dogs. Am J Respir Crit Care Med 1994; 150: 1368-1373.
50. Li X, Moody MR, Engel D, et al., Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000; 102: 1690-1696.
51. Hardin BJ, Campbell KS, Smith JD, et al., TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J Appl Physiol 2008; 104: 694-699.
52. Gosselin LE, Barkley JE, Spencer MJ, et al., Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. Muscle Nerve 2003; 28: 336-343.
53. Grounds MD, Torrisi J,. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004; 18: 676-682.
54. Piers AT, Lavin T, Radley-Crabb HG, et al., Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. Neuromuscul Disord 2011; 21: 132-141.
55. Leeman MF, Curran S, Murray GI,. The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002; 37: 149-166.
56. Uchinami H, Seki E, Brenner DA, et al., Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006; 44: 420-429.
57. Wu N, Jansen ED, Davidson JM,. Comparison of mouse matrix metalloproteinase 13 expression in free-electron laser and scalpel incisions during wound healing. J Invest Dermatol 2003; 121: 926-932.
58. Li H, Mittal A, Makonchuk DY, et al., Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009; 18: 2584-2598.
59. Allen DG, Whitehead NP,. Duchenne muscular dystrophy-what causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol 2011; 43: 290-294.
60. Spencer MJ, Marino MW, Winckler WM,. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 2000; 10: 612-619.